Fcγ receptor polymorphisms as biomarkers for epidermal growth factor receptor antibodies

Journal of Clinical Oncology

Volumn 28, Issue 23, 2010, Pages

  Valerius, Thomas ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FC RECEPTOR; K RAS PROTEIN; PANITUMUMAB; ANTIBODY; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; FCGR1A PROTEIN, HUMAN;

COLORECTAL CANCER; GENE MUTATION; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; LUNG TUMOR; NOTE;

ANTIBODIES; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, IGG;

EID: 77957264305     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.7342     Document Type: Letter

References (9)

1. Shepherd FA, Tsao MS: Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: A riddle, wrapped in a mystery, inside an enigma. J Clin Oncol 28:903-905, 2010
2. Khambata-Ford S, Harbison CT, Hart LL, et al: Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study on cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 28:918-927, 2010
3. Gatzemeier U, Paz-Ares L, Pereira R, et al: Molecular and clinical biomarkers of cetuximab efficacy: Data from the phase III FLEX study in non-small-cell lung cancer. J Thorac Oncol 4:B2.3, 2009 (suppl 1; abstr)
4. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al: Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 184:512-520, 2010
5. Houghton AN, Scheinberg DA: Monoclonal antibody therapies: A 'constant' threat to cancer. Nat Med 6:373-374, 2000
6. Zhang W, Gordon M, Schultheis AM, et al: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25:3712-3718, 2007 (Pubitemid 47372612)
7. Bibeau F, Lopez-Crapez E, Di Fiore F, et al: Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27:1122-1129, 2009
8. Carter PJ: Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357, 2006
9. Schlaeth M, Berger S, Derer S, et al: Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells. Cancer Sci 101:1080-1088, 2010